Biotechnology

Biovica Q1 Interim Report May 2025 - July 2025

September 11, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Partnership agreement with Tempus and continued organic growth in the USA SEK 000s Q1 25/26 Q1 24/25 May-April 24/25 Net sales 2,596 1,714 8,619 Operating profit (loss) -19,334 -23,562 -85,839 Earnings per share, after dilution -0.18 -0.27 -0.95 Number of shares at the end of the period 97,786,384 84,055,560 92,569,248 Cash and cash equivalents at the end of the period 16,305 65,209...

Read more

Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific Antibody

September 10, 2025 10:30 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of a peer-reviewed article in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The paper presents preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5 developed using Alligator's proprietary...

Read more

Groundwork BioAg Announces First Commercial Insetting Deployment of Durable Carbon Removal

September 10, 2025 10:15 AM

Groundwork BioAg, the world's leading producer of mycorrhizal inoculants, today announced a strategic partnership with Beck's to make Rootella® mycorrhizal inoculants and the Rootella Carbon® program available to interested growers through Beck's Grain Attribute program. "Rootella Carbon, a durable carbon dioxide removal (CDR) program based on the application of Rootella mycorrhizal inoculants, increases organic matter in cropland," said Dan...

Read more

Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025

September 9, 2025 11:50 PM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming Clusterbusters 20th Annual U.S. Patient Conference taking place September 11-14, 2025, in Grapevine, Texas (near Dallas/Ft. Worth). This conference is a cornerstone for the cluster...

Read more

NDT Pharmaceuticals Completes Acquisition of Good Salt(TM) Life, LLC

September 9, 2025 5:50 PM

NDT Pharmaceuticals Inc. (OTC:NDTP) ("NDTP" or the "Company") today announced that it has completed the acquisition of Good Salt Life, LLC, an Athens, Georgia-based innovator in biosafety and infection control. The transaction closed on Friday, September 5, 2025. Good Salt Life, a wholly owned subsidiary of NDTP, is a vertically integrated biosafety company that designs, manufactures, and deploys infection control ecosystems combining...

Read more

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

September 9, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced that its Artificial Intelligence (AI) team has been recognized with a special award for excellence in clean code development as part of the National Institute on Aging (NIA) PREPARE Challenge. The award highlights IGC Pharma's achievement in producing well-structured, transparent, and highly organized AI...

Read more

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

September 9, 2025 8:47 AM

Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines. This breakthrough uses virtual chemical screening to identify novel compounds as being potentially toxic, expediting therapeutic discovery and development. Through its application, this platform also addresses...

Read more

AbTherx Appoints Abhi Saharia, PhD, as Chief Business Officer

September 9, 2025 6:00 AM

AbTherx, a biotechnology company pioneering technologies that accelerate antibody discovery, today announced the appointment of Abhishek (Abhi) Saharia, PhD, as Chief Business Officer. In this role, Dr. Saharia will lead all partnerships, collaborations and licensing initiatives, with a focus on amplifying the reach of AbTherx's Atlas™ Mouse platform and advancing its pipeline of disruptive antibody discovery technologies. Dr. Saharia brings...

Read more

Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors

September 8, 2025 11:50 PM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Mr. Marco Mastrodonato to the Company's Board of Directors. Mr. Mastrodonato brings extensive leadership and international business development experience in the pharmaceutical and...

Read more

Alligator Bioscience Has Renegotiated the Outstanding Loan From Fenja Capital and Received Subscription Intentions From Members of the Board of Directors and Management

September 8, 2025 6:00 PM

Alligator Bioscience (STO:ATORX) - Alligator Bioscience AB ("Alligator Bioscience" or the "Company") hereby announces that the Company has renegotiated the outstanding loan from Fenja Capital II A/S ("Fenja Capital"), which originally was raised in June 2024 and subsequently renegotiated in November 2024 and May 2025. As a result of the renegotiation, Fenja Capital agrees to waive the previous condition that 50 per cent of all net proceeds from...

Read more

PulpFixin Names Chad Jenkins Chief Executive Officer

September 8, 2025 10:00 AM

PulpFixin, a leader in sustainable labware, cold chain and packaging solutions for the global scientific community, has appointed Chad Jenkins as chief executive officer, effective immediately. Jenkins, who joined PulpFixin as chief commercial officer in 2024, brings more than three decades of leadership experience in laboratory automation, workflow optimization, product development, manufacturing and distribution. His career has been marked by...

Read more

Lunai Bioworks Strengthens European Strategy Through Restructuring

September 8, 2025 8:50 AM

Lunai Bioworks Inc. (Nasdaq:RENB), an AI-powered drug discovery and biodefense company, today reaffirmed its long-term commitment to European markets and partnerships while announcing the elimination of its legacy subsidiary, Gedi Cube B.V., which has entered bankruptcy proceedings in the Netherlands. "This allows us to move forward in Europe with a leaner, more focused model," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "We...

Read more

Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes

September 8, 2025 8:30 AM

Remedium Bio, Inc. (Remedium) a pioneering genetic medicine company, today announced a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") to advance gene therapies for Type 2 diabetes and obesity using Remedium's Prometheus™ dose-adjustable gene therapy platform. This strategic collaboration will leverage Lilly's deep expertise in metabolic diseases and Remedium's proprietary subcutaneously administered gene...

Read more

Grant Awarded to Investigator-Initiated Phase 2/3 Trial with Mitazalimab in Biliary Tract Cancer

September 8, 2025 3:05 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that an investigator-initiated randomized Phase 2/3 clinical trial will evaluate mitazalimab in combination with FOLFOX chemotherapy in previously treated biliary tract cancer. The trial will investigate mitazalimab's potential in an additional tumor type with significant unmet medical...

Read more

Alligator Bioscience to present at BioStock's "Investing in Life Science" event

September 5, 2025 7:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that CEO Søren Bregenholt, will present at BioStock's Investing in Life Science - From Seed to Success, taking place on Tuesday, 23 September 2025, at the IVA Conference Centre in Stockholm. Event details Date: Tuesday, 23 September 2025 Time: 09:00-17:00 CEST Location: IVA Conference...

Read more

ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners

September 4, 2025 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the ClearPoint Prism® Neuro Laser Therapy System ("ClearPoint Prism") received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to include 1.5T MRI guidance in addition to the previously cleared 3T MRI guidance. This expanded labeling could...

Read more

Lunai Bioworks Inc. Retains American Defense International

September 4, 2025 10:05 AM

Lunai Bioworks Inc. DBA Renovaro Inc. (NASDAQ:RENB), Lunai Bioworks Inc. is an AI-powered tech bio company pioneering safe and responsible generative biology. With proprietary chemical datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats, today announced that it had retained American...

Read more

Revalia Bio Raises $14.5M Seed Round to Launch Human Data Trial Platform and Redefine Drug Development

September 4, 2025 10:00 AM

Revalia Bio Inc., announced a 14.5M seed funding round to support their launch of ‘Human Data Trials' - a new category of pre-clinical research that gives drug developers early, predictive insights from real, functional human organs. The round was co-led by America's Frontier Fund and Sierra Ventures with participation from Roger Ferguson, former Vice Chair of the U.S. Federal Reserve and a member of the Board of Directors at Alphabet, and other...

Read more

MygoGenesis Releases White Paper Detailing aLAL(TM) - a Sustainable, Lab-Grown Amebocyte Lysate Designed for Reliable Endotoxin Testing

September 4, 2025 8:00 AM

MygoGenesis, a biotechnology company pioneering cell-origin materials through its Mygotic Process™, today announced the release of a new white paper, "Advances in Using Sustainably Generated Amebocytes to Ensure Affordable and Effective Endotoxin Testing." The paper presents scientific and operational evidence supporting aLAL™ - a lysate produced from lab-grown amebocytes - as a sustainable path to high-quality bacterial endotoxin testing. ...

Read more

Aspira Women’s Health Appoints New Chief Financial Officer

September 4, 2025 7:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Brian Hungerford as Chief Financial Officer, effective September 2, 2025. "We are pleased to announce the addition of Mr. Hungerford to our executive team," commented Mike Buhle,...

Read more